Sandoz launches authorized generic version of Diovan® in the US

Princeton, New Jersey, July 8, 2014 – Sandoz today announced the US introduction of an authorized generic version of Diovan® (valsartan) tablets for the treatment of high blood pressure (HBP).

​This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT® (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP, a condition that affects approximately one in three US adults.1,2

“We are pleased to offer …

/by

Sandoz brings together key French stakeholders to discuss biosimilars

Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.

Read more

/by